Nemonapride

Nemonapride

Clinical data
Trade names	Emilace (JP)
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Rx-only (JP)
Identifiers
IUPAC name N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide
CAS Number	75272-39-8
PubChem CID	4452
IUPHAR/BPS	983
ChemSpider	4297
UNII	Q88T5P3444
KEGG	D01468 Y
ChEBI	CHEBI:64217
ChEMBL	ChEMBL20734
PDB ligand	AQD (PDBe, RCSB PDB)
Chemical and physical data
Formula	C21H26ClN3O2
Molar mass	387.91 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1C(CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl
InChI InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26) Key:KRVOJOCLBAAKSJ-UHFFFAOYSA-N
(verify)

Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in May 1991. Nemonapride acts as a D₂ and D₃ receptor antagonist, and is also a potent 5-HT_1A receptor agonist. It has affinity for sigma receptors.

See also

• Benzamide